JP Morgan Private Wealth Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-23,449
Closed -$1.02M 1391
2017
Q4
$1.02M Buy
+23,449
New +$997K 0.01% 649

Other funds holding XPH

JP Morgan Private Wealth Advisors's XPH Position: Q1 2018 in Review

JP Morgan Private Wealth Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2018, closing a stake of 23,449 shares — an estimated $1.02M sold.

JP Morgan Private Wealth Advisors first reported a position in XPH in Q4 2017 and held it in 1 quarter. The position peaked at $1.02M in Q4 2017. 75 funds tracked by Wall St. Rank hold XPH as of Q1 2018.

  • JP Morgan Private Wealth Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 23,449 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2018, an estimated $1.02M.
  • JP Morgan Private Wealth Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2017 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.02M in Q4 2017.
  • 75 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2018.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2018, filed 10 May 2018.